G1 therapeutics, inc. (GTHX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Operating expenses
Research and development

91,356

89,002

83,588

76,520

71,416

70,683

66,681

64,862

60,144

53,881

44,500

36,900

0

0

0

General and administrative

43,625

40,039

34,986

28,852

23,026

18,603

13,801

10,727

9,171

7,087

5,799

4,899

0

0

0

Total operating expenses

134,981

129,041

118,574

105,372

94,442

89,286

80,482

75,589

69,315

60,968

50,299

41,799

0

0

0

Operating loss

-134,981

-129,041

-118,574

-105,372

-94,442

-89,286

-80,482

-75,589

-69,315

-60,968

-50,299

-41,799

0

0

0

Other income (expense)
Other income

5,463

6,594

7,476

6,720

5,612

3,998

2,305

1,729

1,129

888

643

365

0

0

0

Change in fair value in warrant liability and other liabilities

-

-

-

-

-

-

-

-

-

41

0

0

0

-

-

Total other income, net

5,463

6,594

7,476

6,720

5,612

3,998

2,305

1,729

1,129

847

602

324

0

0

0

Net loss

-129,518

-122,447

-111,098

-98,652

-88,830

-85,288

-78,177

-73,860

-68,186

-60,121

-49,697

-41,475

0

0

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

4,757

5,962

6,948

0

0

0

Net loss attributable to common stockholders

0

0

-

-

0

-85,288

-

-

-68,475

-64,878

-55,659

-48,423

0

0

0

Net loss per share attributable to common stockholders, basic and diluted

-0.82

-0.94

-0.86

-0.82

-0.64

-0.65

-0.59

-0.64

-0.70

9.31

-0.55

-1.09

-11.24

-5.21

-5.63

Weighted average common shares outstanding, basic and diluted

37,659

37,586

37,540

37,470

37,396

37,203

33,829

32,781

29,360

28,768

28,318

14,208

1,496

1,490

1,486